COVID-19 SARS-CoV-2 InfectionNCT07900139
A Study to Learn About COVID-19 Antivirals in People With SARS-CoV-2 Infection From 2023-2026
An observational study of COVID-19 SARS-CoV-2 Infection, run by Pfizer at 1 site in United States.
Trial summary
The purpose of this study is to learn about the management, treatment, healthcare resource utilization (HCRU), and outcomes of individuals with SARS-CoV-2 infection. This is a retrospective secondary analysis of administrative claims data from 2023-2026, therefore there is no enrollment or participation required. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19 SARS-CoV-2 Infection
- What is being tested?
- Patients with COVID-19
- How many people
- 1 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Jul 2026to 30 Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Individuals in claims/Electronic health records (EHR) Data Sources
Who may be able to join
- Admitted to the hospital (any cause)
- COVID-19 diagnosis
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: CURRENT TREATMENT MANAGEMENT AND OUTCOMES OF INPATIENTS WITH SARS-COV-2
The purpose of this study is to learn about the management, treatment, healthcare resource utilization (HCRU), and outcomes of individuals with SARS-CoV-2 infection.
This is a retrospective secondary analysis of administrative claims data from 2023-2026, therefore there is no enrollment or participation required. The study will describe and evaluate the real-world management, treatment, HCRU, and outcomes of individuals with SARS-CoV-2 infection.
- Conditions
- COVID-19 SARS-CoV-2 Infection
- Being tested
- Patients with COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patients with COVID-19Other
Treatment of Patients with COVID-19 from 2023-2026
| Study group | Role | What they receive |
|---|---|---|
| Patients with COVID-19 | Patients with COVID-19 from 2023-2026 Receives: Other: Patients with COVID-19 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of individuals with COVID-19 by antiviral treatment
Measured: Inpatients with COVID-19 between 2023-2026
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2026
- Study start20 Jul 2026
- Primary completion30 Oct 2026 (estimated)
- Study completion30 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19 SARS-CoV-2 InfectionStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07900139
- Sponsor's protocol ID
- C4671074
- Status last verified
- Oct 2026
- First submitted
- 21 Oct 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CURRENT TREATMENT MANAGEMENT AND OUTCOMES OF INPATIENTS WITH SARS-COV-2
- ClinicalTrials.gov ID
- NCT07900139
- Acronym / sponsor ID
- C4671074
- Conditions
- COVID-19 SARS-CoV-2 Infection
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1 participants (estimated)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 20 Jul 2026 (actual)
- Primary completion
- 30 Oct 2026 (estimated)
- Study completion
- 30 Oct 2026 (estimated)
- First posted
- 28 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to learn about the management, treatment, healthcare resource utilization (HCRU), and outcomes of individuals with SARS-CoV-2 infection.
This is a retrospective secondary analysis of administrative claims data from 2023-2026, therefore there is no enrollment or participation required. The study will describe and evaluate the real-world management, treatment, HCRU, and outcomes of individuals with SARS-CoV-2 infection.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with COVID-19 | – | Other: Patients with COVID-19Patients with COVID-19 from 2023-2026 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Individuals in claims/Electronic health records (EHR) Data Sources
Key inclusion criteria (2 listed)
- Admitted to the hospital (any cause)
- COVID-19 diagnosis
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patients with COVID-19Treatment of Patients with COVID-19 from 2023-2026 | Other | Patients with COVID-19 |
Primary outcome
Percentage of individuals with COVID-19 by antiviral treatment
Time frame: Inpatients with COVID-19 between 2023-2026
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: No. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for COVID-19 SARS-CoV-2 Infection
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 SARS-CoV-2 Infection, run by Pfizer at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of individuals with COVID-19 by antiviral treatment (time frame: Inpatients with COVID-19 between 2023-2026). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.